Product/Composition:- | Intravenous Immunoglobulin (IVIG) |
---|---|
Strength:- | 5% and 10% |
Form:- | Intravenous infusion |
Reference Brands:- | Gammagard, Flebogamma, Privigen, Octagam, Kiovig, Carimune(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
IVIG provides pooled immunoglobulin G (IgG) antibodies, modulating the immune response. It neutralizes pathogens, regulates autoimmune activity, and boosts immune function. Benefits include treating immunodeficiency, autoimmune diseases, and inflammatory conditions, reducing infection risk, improving symptoms, and supporting immune system regulation for better patient outcomes.
Intravenous Immunoglobulin (IVIG) injection, marketed as Gammagard, Privigen, Octagam, and others, is approved in the US by the FDA and in the EU via EMA for treating immunodeficiency and autoimmune disorders. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety, manufacturing standards, and pharmacovigilance plans. In the US, the FDA conducts rigorous review, while in the EU, EMA guidelines ensure regional compliance. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Ensuring regulatory compliance is essential for the safe, effective, and timely approval of IVIG products worldwide, supporting improved patient outcomes across multiple conditions.